Research programme: RNA based immunotherapeutics- Rigontec

Drug Profile

Research programme: RNA based immunotherapeutics- Rigontec

Alternative Names: ImOl 200; ImOl 201; Retinoic acid inducible gene I receptor agonists - Rigontec

Latest Information Update: 28 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rigontec
  • Class Gene therapies; Oligonucleotides; RNA; Small molecules
  • Mechanism of Action DDX58 protein stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Inflammation
  • No development reported Cancer; Viral infections

Most Recent Events

  • 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in Germany
  • 28 Feb 2018 No recent reports of development identified for preclinical development in Viral-infections in Germany
  • 27 Oct 2017 Rigontec has been acquired by Merck & Co
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top